Welcome to our dedicated page for Genix Pharmaceut news (Ticker: GENPF), a resource for investors and traders seeking the latest updates and insights on Genix Pharmaceut stock.
Genix Pharmaceuticals Corporation (TSXV: GENX, OTCQB: GENPF) is a Canadian nutraceutical and generic ophthalmic drugs company whose news flow reflects both its product focus and its capital markets activity. Company news releases describe a business centered on the research, development, manufacture, licensing and sales of novel and generic ophthalmic drugs, along with evidence-based proprietary over-the-counter nutraceuticals and other single molecule generic drugs.
News items for Genix often highlight ophthalmic and healthcare positioning, including references to prescription and OTC ophthalmological products and products awaiting Health Canada approval. The company also reports on its plans to market ophthalmic drugs in Canada and globally and nutraceutical products in North America and other select countries, providing context for updates related to product development and regulatory progress.
Another major theme in Genix news coverage is financing and securities-related activity. The company has issued detailed releases on non-brokered private placements of units comprising common shares and transferable common share purchase warrants, clarifications to placement terms, and the intended use of proceeds for general working capital and potential funding for new products. It has also reported on warrant repricing, proposed and approved amendments to warrant exercise prices, accelerator terms and expiry dates, and corrections to previously disclosed warrant numbers.
Corporate governance updates, such as annual general meeting results, director elections, auditor appointments, stock option plan approvals and option repricing, also appear in the news stream. Investors and observers can use this page to review historical announcements related to Genix’s product focus, regulatory aspirations, financing structures, and shareholder matters in one place.
Genix Pharmaceuticals (GENPF) corrected terms for a recently closed non‑brokered private placement announced earlier. The Company clarified the Unit issue price was $0.05 per Unit (not $0.10). The Company issued 2,000,000 Units at $0.05 for total gross proceeds of $100,000. Each Unit includes one common share and one transferable warrant. Each warrant permits purchase of one additional share at $0.10 per share and expires on September 4, 2027. All other private placement terms remain unchanged.
Genix Pharmaceuticals (TSXV: GENX) has completed a non-brokered private placement, raising $100,000 through the issuance of 2,000,000 units at $0.10 per unit. Each unit comprises one common share and one transferable warrant, with warrants exercisable at $0.10 per share until September 04, 2027.
The placement was entirely subscribed by company insiders - the President and CEO. The proceeds will be used for general working capital and potential new product funding. All securities issued are subject to a four-month hold period, and the offering completion remains subject to TSX Venture Exchange approval.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Genix Pharmaceut (GENPF)?
What is the market cap of Genix Pharmaceut (GENPF)?
